Methods of treating obesity
OwnerMartin Myersinventor
Life of this patent
Estimating the term…
Abstract
The invention provides methods of modulating appetite, body weight and/or reproductive function in a mammal by modulating leptin receptor long form (LRb)-STAT3 signaling.
Claims44
A method of modulating appetite or body weight in a mammal, comprising:
- identifying a mammal in need of modulating appetite and/or body weight;
- and
- administering to the mammal an agent that modulates leptin receptor long form (LRb)-STAT3 signaling.
A non-human transgenic rodent whose genome is heterozygous or homozygous for an engineered mutation in an LRb gene, wherein the mutation affects body weight or appetite in the mammal, but does not substantially affect reproductive function.
A cell having a mutation in the LRb gene wherein the mutation causes a disruption in LRb-STAT3 signaling within the cell but does not cause a disruption in LRb-ERK signaling.
A method of evaluating an agent for the ability to modulate appetite or body weight, the method comprising:
- administering a test agent to a transgenic mammal having a mutation in the LRb gene wherein the mutation causes a reduction in LRb-STAT3 signaling but not in LRb-ERK signaling;
- and
- determining whether the test agent affects appetite or body weight in the transgenic mammal.
A method of evaluating an agent for the ability to modulate appetite or body weight, the method comprising:
- administering a test agent to a cell or tissue having a mutation in the LRb gene wherein the mutation causes a disruption in LRb-STAT3 signaling but not in LRb-ERK signaling;
- and
- determining whether the test agent affects LRb-STAT3 signaling in the cell or tissue.
A method of determining if a subject is at risk for obesity, the method comprising:
- (a) evaluating a LRb-STAT3 activity in the subject, and (b) correlating the LRb-STAT3 activity to a risk for obesity, wherein a lower LRb-STAT3 activity in the subject compared to a reference value indicates that the subject is at risk for obesity.
A method of determining if a subject is at risk for obesity, the method comprising:
- (a) determining the presence or absence of a genetic lesion in the LRb gene of a subject, wherein the genetic lesion disrupts the tyrosine located at about amino acid 1141 of LRb, and (b) correlating the presence or absence of the genetic lesion to a risk for obesity, wherein the presence of the genetic lesion is indicative of risk for obesity in the subject.
A method of modulating fertility in a mammal, the method comprising modulating LRb-ERK signaling to thereby modulate fertility.
A method of modulating height in a mammal, the method comprising modulating LRb-ERK signaling to thereby modulate height.
A non-human transgenic rodent whose genome is heterozygous or homozygous for an engineered mutation in an LRb gene, wherein the mutation affects reproductive function or height in the mammal, but does not substantially affect body weight or appetite.
A cell having a mutation in the LRb gene wherein the mutation causes a disruption in LRb-ERK signaling within the cell but does not cause a disruption in LRb-STAT3 signaling.
A method of evaluating an agent for the ability to modulate reproductive function or height, the method comprising:
- administering a test agent to a transgenic mammal having a mutation in the LRb gene wherein the mutation causes a reduction in LRb-ERK signaling but not in LRb-STAT signaling;
- and
- determining whether the test agent affects reproductive function or height in the transgenic mammal.
A method of evaluating an agent for the ability to modulate reproductive function or height, the method comprising:
- administering a test agent to a cell or tissue having a mutation in the LRb gene wherein the mutation causes a reduction in LRb-ERK signaling but not in LRb-STAT3 signaling;
- and
- determining whether the test agent affects LRb-ERK signaling in the cell or tissue.
A method of determining if a subject is at risk for a reproductive disorder, the method comprising:
- (a) evaluating a LRb-ERK activity in the subject, and (b) correlating the LRb-ERK activity to a risk for reproductive disorder, wherein a lower LRb-ERK activity in the subject compared to a reference value indicates that the subject is at risk for reproductive disorder.
A method of determining if a subject is at risk for reproductive disorder, the method comprising:
- (a) determining the presence or absence of a genetic lesion in the LRb gene of a subject, wherein the genetic lesion disrupts the tyrosine located at about amino acid 985 of LRb, and
- (b) correlating the presence or absence of the genetic lesion to a risk for reproductive disorder, wherein the presence of the genetic lesion is indicative of risk for reproductive disorder in the subject.
An isolated LRb polypeptide wherein the tyrosine residue corresponding to murine LRb Tyr 1138 has been altered, but the amino acid residue corresponding to murine LRb Tyr 985 has not been altered.
Dependencies are inferred from the claim text.